2024 Outlook: The acquisition will have a low single-digit negative impact on operating profit growth and reduce free cash flow by the $11.7 billion USD ...
FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite concerns from Eli Lilly.
Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal ...
Novo Nordisk's (NVO) acquisition of three Catalent (CTLT) production sites to close soon as its parent wins regulatory nod for the $16.5B deal.
Catalent is an attractive target for Novo Holdings because it is a subcontractor that already helps manufacture the anti-obesity drug Wegovy.
Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products ...
Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy. According to the terms of the deal, Novo Holdings ...
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies ...
The $16.5 billion acquisition aims to boost Wegovy production while sparking discussions about potential competitive impacts in the US and EU.
Catalent is pictured at 1300 S. Patterson Drive in Bloomington. Catalent and Novo Holdings announced Dec. 14 that the companies had fulfilled all regulatory ...
Novo Holdings, the major shareholder of Danish pharmaceutical company Novo Nordisk, is close to finalizing its purchase of Catalent.
The agreement, initially announced in February, involves Novo Holdings acquiring Catalent and Novo Nordisk purchasing three fill-finish manufacturing sites ...